A global leader in the
development of Epigenetic drugs
Strategy. Discovery. Development.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015),
ORYZON is a clinical stage biopharmaceutical company that discovers and develops innovative epigenetics-based therapeutics for patients with cancer and neurodegenerative disorders. We are able to identify biomarkers through our genomics and proteomics platforms and to translate them in advanced and personalized therapies.
is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com